Lilly/Daiichi Submit Prasugrel; Showdown With Plavix Timed For Second Half
Executive Summary
Lilly and Daiichi Sankyo plan to launch the antiplatelet drug prasugrel immediately after it is approved, supported by an extensive sales force including representatives from both companies
You may also be interested in...
AstraZeneca In The “Transparency” Era: An Interview With CEO David Brennan
If you visit AstraZeneca's offices in Washington, D.C., your name has to be on a list. After you get your badge, you show it at the elevator bank to a guard, who, in a throwback to operators of yore, steps inside with you to unlock the keypad and send you on your way
AstraZeneca In The “Transparency” Era: An Interview With CEO David Brennan
If you visit AstraZeneca's offices in Washington, D.C., your name has to be on a list. After you get your badge, you show it at the elevator bank to a guard, who, in a throwback to operators of yore, steps inside with you to unlock the keypad and send you on your way
Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market
Lilly will protect Zyprexa's market share from generic competition by emphasizing the atypical antipsychotic's efficacy and by focusing on the institutional, urgent-need patient market, President and incoming CEO John Lechleiter said during the company's Jan. 29 sales and earnings call